New cancer drug YL202 enters first human trials

NCT ID NCT05653752

Ongoing Disease control Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called YL202 in about 80 people with advanced lung or breast cancer that has not responded to standard treatments. The drug is given by IV every three weeks. The main goal is to check safety and find the right dose, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: YL202 (a drug given intravenously every 3 weeks)
What this could lead to: If it works, this could point toward a new treatment option for certain advanced lung and breast cancers that have stopped responding to standard therapies.
What could go wrong: This is a very early (Phase 1) and small study focused on safety and dosing, not effectiveness. Many drugs fail at this stage, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

BRCR Global

Plantation, Florida, 33322, United States
Fujian Cancer Hospital

Fuzhou, Fujian, 350014, China
Hunan Cancer Hospital

Changsha, Hunan, 410013, China
Jilin Provincial Cancer Hospital

Changchun, Jilin, 130012, China
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Next Oncology-Dallas

Irving, Texas, 75039, United States
Next Oncology-Virginia

Fairfax, Virginia, 22031, United States
Summit Cancer Center

Spokane Valley, Washington, 99216, United States
Taizhou Hospital of Zhejiang Province

Taizhou, Zhejiang, 317099, China
The First Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310003, China
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
UT health east Texas HOPE Cancer Center

Tyler, Texas, 75701, United States
Zhejiang Cancer Hospital

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.